Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Serenelli

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Giornale Italiano Di Cardiologia (2006)|November 26, 2024
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)]Aldostefano Porcari, Cristina Chimenti, Marco Merlo, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|July 31, 2024
Temporal implementation of a regional referral pathway in transthyretin cardiac amyloidosis: Emilia-Romagna experienceSimone Longhi, Elena Biagini, Pietro Guaraldi, et al.
Journal of the American College of Cardiology|June 12, 2024
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid CardiomyopathyAldostefano Porcari, Francesco Cappelli, Christian Nitsche, et al.
JACC. Cardiovascular Imaging|October 28, 2025
Analysis of Calcium Scores in Severe Aortic Stenosis Patients With and Without Cardiac Amyloidosis: The CAUSATIVE StudyMatteo Serenelli, Paolo Cimaglia, Aldostefano Porcari, et al.
European Heart Journal|August 22, 2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, et al.
Journal of the American Heart Association|November 12, 2025
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin CardiomyopathyAlberto Aimo, Martina Nesti, Giuseppe Vergaro, et al.
European Heart Journal|March 22, 2023
Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosisMuhammad Umaid Rauf, Philip N Hawkins, Francesco Cappelli, et al.
Frontiers in Neurology|September 15, 2025
Monitoring patients and asymptomatic carriers with hereditary transthyretin amyloidosis: regional protocol of Emilia-Romagna ATTR working groupPietro Guaraldi, Isabella Allegri, Alessandra Ariatti, et al.
European Journal of Heart Failure|November 29, 2025
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidisAldostefano Porcari, Paolo Milani, Simone Longhi, et al.
European Journal of Heart Failure|March 12, 2023
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network studyGiacomo Tini, Paolo Milani, Mattia Zampieri, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Giornale Italiano Di Cardiologia (2006)|November 26, 2024
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)]Aldostefano Porcari, Cristina Chimenti, Marco Merlo, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|July 31, 2024
Temporal implementation of a regional referral pathway in transthyretin cardiac amyloidosis: Emilia-Romagna experienceSimone Longhi, Elena Biagini, Pietro Guaraldi, et al.
Journal of the American College of Cardiology|June 12, 2024
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid CardiomyopathyAldostefano Porcari, Francesco Cappelli, Christian Nitsche, et al.
JACC. Cardiovascular Imaging|October 28, 2025
Analysis of Calcium Scores in Severe Aortic Stenosis Patients With and Without Cardiac Amyloidosis: The CAUSATIVE StudyMatteo Serenelli, Paolo Cimaglia, Aldostefano Porcari, et al.
European Heart Journal|August 22, 2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, et al.
Journal of the American Heart Association|November 12, 2025
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin CardiomyopathyAlberto Aimo, Martina Nesti, Giuseppe Vergaro, et al.
European Heart Journal|March 22, 2023
Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosisMuhammad Umaid Rauf, Philip N Hawkins, Francesco Cappelli, et al.
Frontiers in Neurology|September 15, 2025
Monitoring patients and asymptomatic carriers with hereditary transthyretin amyloidosis: regional protocol of Emilia-Romagna ATTR working groupPietro Guaraldi, Isabella Allegri, Alessandra Ariatti, et al.
European Journal of Heart Failure|November 29, 2025
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidisAldostefano Porcari, Paolo Milani, Simone Longhi, et al.
European Journal of Heart Failure|March 12, 2023
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network studyGiacomo Tini, Paolo Milani, Mattia Zampieri, et al.
Pageof 9